“TARGETING MULTI-MICROBIAL INFECTION IN CHRONIC WOUNDS THROUGH TRIPLE ANTIBIOTIC NANOEMULGEL FORMULATION”

Objective: Chronic diabetic wounds are challenging to treat due to multi-microbial infections. This study developed an innovative triple-antibiotic nanoemulgel formulation (TANF) that integrates metronidazole, norfloxacin, and mupirocin, targeting anaerobic bacteria, Gram-negative bacteria, and Gram-positive bacteria, respectively. The objective was to create a wide-spectrum, effective topical therapy with superior drug delivery characteristics. Methods: Six nanoemulgel batches were prepared using high-speed homogenization, with 0.5% Hydroxypropyl Methylcellulose (HPMC) E15 as the gelling agent in batch F1. The formulation incorporated tea tree oil and coconut oil as penetration enhancers. Comprehensive physicochemical characterization included drug content, pH, spreadability, skin permeability, and in vitro drug release studies. Drug release kinetics was analyzed, and stability investigations were initiated. Results: Batch F1 demonstrated optimal performance, achieving drug release of 90.12% Metronidazole, 89.56% Norfloxacin, and 90.79% Mupirocin within 24 h. The formulation maintained pH levels between 6-6.5, over 95% drug content, and excellent spreadability. Higuchi kinetics governed the drug release, and the inclusion of penetration enhancers significantly improved skin permeability. The nanoemulgel exhibited reduced greasiness and a dual control release mechanism, addressing limitations in traditional topical formulations. Conclusion: The developed TANF demonstrated strong, broad-spectrum antimicrobial activity and enhanced drug delivery, making it a promising topical therapy for chronic diabetic wounds. Its optimized formulation ensures effective microbial coverage and improved patient compliance. Ongoing stability studies will confirm its long-term safety and efficacy.